High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019-Reference-Cited by-全球学者库

High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019

Published:2020-03-01 Issue:3 Volume:7 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

Cao Wei¹,Liu Xiaosheng²,Bai Tao³,Fan Hongwei¹,Hong Ke³,Song Hui³,Han Yang¹,Lin Ling¹,Ruan Lianguo³,Li Taisheng¹

Affiliation:

1. Department of Infectious Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China

2. Tsinghua-Peking Center for Life Sciences, School of Medicine, Tsinghua University, Beijing, China

3. Department of Infectious Diseases, Jin Yin-tan Hospital, Wuhan, China

Abstract

Abstract The outbreak of coronavirus disease 2019 (COVID-19) has spread rapidly in China. Until now, no definite effective treatment has been identified. We reported on 3 patients with severe COVID-19 who received high-dose intravenous immunoglobulin (IVIg) with satisfactory recovery. Based on these observations, randomized studies of high-dose IVIg should be considered in deteriorating patients infected with COVID-19.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Link

http://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofaa102/32959155/ofaa102.pdf

Reference17 articles.

1. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China;Huang;Lancet,2020

2. A novel coronavirus from patients with pneumonia in China, 2019;Zhu;New Engl J Med,2020

3. CT imaging features of 2019 novel coronavirus (2019-nCoV);Chung;Radiology,2020

Cited by 313 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multifaceted Tissue-Protective Functions of Polyvalent Immunoglobulin Preparations in Severe Infections—Interactions with Neutrophils, Complement, and Coagulation Pathways;Biomedicines;2023-11-10

2. Integrated longitudinal multi-omics study identifies immune programs associated with COVID-19 severity and mortality in 1152 hospitalized participants;2023-11-06

3. Clinical efficacy of immunoglobulin on the treatment of severe fever with thrombocytopenia syndrome: a retrospective cohort study;eBioMedicine;2023-10

4. Targeting cytokine storm as the potential anti-viral therapy: Implications in regulating SARS-CoV-2 pathogenicity;Gene;2023-09

5. COVID-19: a modern trigger for Guillain-Barre syndrome, myasthenia gravis, and small fiber neuropathy;Frontiers in Neuroscience;2023-08-30